IRWD vs MDXG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Ironwood Pharmaceuticals presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a critical lack of equity, as evidenced by a negative Price/Book ratio of -2.26. While the stock has seen a massive 1-year price surge, this is fundamentally unsupported by a 47.3% collapse in year-over-year revenue and a significant disconnect between the current price ($3.63) and the growth-based intrinsic value ($1.05). Heavy insider selling totaling nearly $22 million further signals a lack of confidence from company leadership.
MDXG presents a stark divergence between fundamental value and market sentiment. With a Piotroski F-Score of 4/9 (Stable) and an exceptionally clean balance sheet (Debt/Equity 0.09), the company is financially healthy and significantly undervalued relative to its Intrinsic Value of $9.44 and Analyst Target of $9.67. However, the assessment is tempered to neutral due to a severe technical collapse (0/100 trend) and bearish insider activity, suggesting that while the stock is a value bargain, it lacks a current catalyst for reversal.
Compare Another Pair
Related Comparisons
IRWD vs MDXG: Head-to-Head Comparison
This page compares Ironwood Pharmaceuticals, Inc. (IRWD) and MiMedx Group, Inc. (MDXG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.